MAPT and tauopathy: Tau-targeting proteolysis-targeting chimeras (PROTACs), which can lead to polyubiquitination and proteasome-mediated degradation of the protein, were developed to reduce t-tau and p-tau levels in tauopathy mouse models [216, 217].